Articles tagged with Cancer Patients
Researchers develop a new method to analyze genetic sequences, known as SURVIV, which can predict cancer patients' survival times with greater accuracy. This technique may also enable doctors to target specific genetic sequences that could fight disease, according to the study published in Nature Communications.
A new breath test has been developed to identify lung cancer after surgery, using a simple, affordable process that analyzes carbonyl volatile organic compounds in exhaled breath. The test shows great potential for detecting lung cancer at any point, both as primary screening and post-surgery monitoring.
The Harold Alfond Foundation's charitable gift will support The Jackson Laboratory's efforts to enhance cancer diagnostics and treatment in Maine. JAX aims to provide precision cancer care using the latest genetic technologies to determine the best treatment for each patient.
Scientists identified 11 major groups of AML, each with unique genetic changes driving the disease. The study's findings improve diagnosis and treatment for young AML patients by predicting survival rates based on genetic complexity.
A study by Loyola Medicine found that mesothelioma surgery, specifically pleurectomy and decortication, improves quality of life in patients. The procedure can control fluid buildup, improve breathing, and reduce cancer pain, with benefits observed as early as one month after surgery.
A study published in JNCI found that patients treated at high-volume centers had statistically significant longer overall survival compared to those at low-volume centers. The difference was greater than 10% at two years, suggesting improved disease control and management of adverse effects.
Regular skin checks during PCP visits improve melanoma detection and treatment outcomes. Thinner melanomas detected through screening have a better prognosis than thicker ones.
Researchers from Scripps Research Institute have been awarded $1.3 million to optimize probes for a new cancer treatment approach. The study focuses on the retinoic acid receptor-related orphan receptors (ROR) gamma and molecules that bind to it, aiming to trigger immune cells to attack tumor cells.
Researchers analyzed data from Washington State hospital database and found no difference in cancer rates between patients who received rhBMP and those who did not. The study's findings suggest that additional follow-up is needed to rule out any longer-term increase in cancer risk.
A study found that nearly two-thirds of younger cancer patients with metastatic disease received hospitalization, emergency room visits, or chemotherapy in their last 30 days. Researchers call for earlier discussions on palliative care to improve quality of life.
Researchers from Thomas Jefferson University have identified a panel of microRNAs in blood samples that can predict patients at high risk of developing hepatocellular carcinoma, the most common type of liver cancer, in individuals infected with hepatitis B virus.
Preliminary results suggest that the selinexor combination regimen is active in relapsed and refractory multiple myeloma. Of 10 evaluable patients, two each achieved a very good partial response, a partial response, and a minimal response.
A Phase II clinical trial conducted by MD Anderson Cancer Center found that nivolumab significantly improves outcomes for patients with squamous cell carcinoma of the anal canal, with a control rate of 70%. The study enrolled 39 patients and demonstrated efficacy in both HIV-positive and non-HIV positive populations.
A clinical trial shows atezolizumab, a checkpoint inhibitor, is effective in treating advanced bladder cancer, shrinking tumors and stopping new growth. The drug was well-tolerated, with mild side effects, and half of patients responded within 15 weeks.
A clinical trial found that patients with tumors overexpressing DLL3 responded better to the experimental drug rovalpituzumab tesirine (Rova-T), achieving stabilization of disease and significant tumor reductions. The results suggest Rova-T may be a promising treatment option for advanced small cell lung cancer.
A Phase 3 clinical trial found that patients with high-risk neuroblastoma who received two autologous stem-cell transplants had higher event-free and overall survival rates compared to those who underwent a single transplant. The study also showed improved outcomes when immunotherapy was added to the treatment regimen.
A Phase I/II clinical trial found that nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of PD-L1 marker presence. The treatment was well-tolerated and showed a median survival of at least one year for 45.6% of patients.
Researchers at H. Lee Moffitt Cancer Center report a safe and effective treatment regimen for recurrent high-grade glioma brain tumors, with durable disease control in three patients. The combination of pembrolizumab, bevacizumab, and radiation therapy shows promise as a potential new approach to treating these patients.
A new pre-surgery technique using an expandable tube may make colostomy bags redundant for emergency bowel cancer patients. The study found that less than half of those who had their bowel unblocked needed a colostomy bag, while more than two-thirds required one after emergency surgery.
Researchers at UT Southwestern Medical Center discovered that between 14 to 25 percent of lung cancer patients also have immune disease, making them unsuitable for immunotherapy treatments. This finding raises critical questions about the effectiveness and toxicity of these treatments among patients with autoimmune diseases.
A study found that genes involved in the Wnt signaling pathway are more frequently altered in younger patients with colorectal cancer. This pathway drives the growth and proliferation of cancer stem cells. The research suggests targeting this pathway may be a promising strategy for treating aggressive CRC in young patients
A study found that while overall colorectal cancer rates are decreasing, the incidence of late-stage cancer in young patients is increasing. The study, which analyzed data from Colorado patients, reveals a significant rise in late-stage CRC diagnoses among those under 50.
Researchers from UH Seidman Cancer Center will present data on a new online tool for estimating individualized survival probabilities in patients with newly diagnosed glioblastoma. The studies also explore promising new treatments, including pembrolizumab for head and neck squamous cell carcinoma, and improve patient participation in c...
A University of Colorado study found that Hispanic white and non-Hispanic black young adults are more likely to die from cancer than their white counterparts, with mortality risks ranging from 1.36 to 1.77 times higher.
A recent study found that over one-in-four cancer patients struggle to afford medical care, leading to missed appointments and prescription delays. The researchers highlight the need for support programs to help patients navigate financial difficulties.
A new study finds that delivering genetic test results to patients at risk for cancer-causing mutations over the phone reduces costs and access burdens. Patients who received phone counseling reported fewer barriers to accessing genetic counseling services than those who received in-person counseling.
Dr. Glen Weiss presents five innovative cancer studies at ASCO, including liquid biopsies for predicting treatment improvements and promising results with avelumab against recurrent-refractory ovarian cancer. Brigatinib shows substantial antitumor activity in ALK non-small cell lung cancer patients.
Researchers at the University of Rochester Medical Center found that exercise can significantly reduce neuropathic symptoms in cancer patients undergoing chemotherapy. The study, which involved over 300 participants, showed that a six-week walking routine with gentle resistance-band training reduced pain and sensitivity to cold. Exerci...
In a phase 3 study, Lutathera treatment results in improved progression-free survival and higher objective radiographic response rates compared to Octreotide LAR. The safety profile of Lutathera was also favorable with low-grade adverse events.
A Moffitt Cancer Center study found that combining nivolumab and ipilimumab is an active treatment option for small cell lung cancer patients who have failed initial therapy. The two-drug immunotherapy regimen resulted in responses that lasted longer than many other investigational agents, with 20% of patients showing a response.
A study of nearly 49,000 obese patients found that bariatric surgery significantly lowers mortality rates, with a 57% reduction in all-cause deaths compared to non-surgical patients. Cardiovascular disease and cancer were the leading causes of death in both groups.
Researchers discovered that Pten's phosphatase activity counteracts PI3 kinase activity, leading to uncontrolled cell proliferation and survival. Mutant mice lacking critical amino acids form tumors at high frequency, making them susceptible to targeted cancer therapy.
A new study from Mount Sinai researchers reports a high success rate for a personalized medicine program that uses an integrated genomic approach to guide cancer treatment. The program led to therapeutic recommendations for 91% of patients, outperforming targeted cancer panels in clinical use.
A study by University of Houston Graduate College of Social Work researchers examines the perceptions and preferences of older Latinos with advanced cancer regarding news on their diagnosis or prognosis. The investigation aims to identify culturally appropriate training for physicians and providers, promoting quality end-of-life care.
Incorporating laboratory mice that are old and obese into immunotherapy treatments for cancer can hasten therapeutic breakthroughs. The use of young, healthy mice is often preferred, but this approach may not accurately reflect the human immune system's response to treatment.
A new blood test has identified a subset of patients with stomach cancer who are most likely to respond to treatment. The test measures the number of copies of the FGFR2 gene in cancer DNA circulating in the bloodstream, revealing that tumours with many copies of this gene were particularly susceptible to an experimental drug.
Researchers developed a new method of diagnosing colorectal cancer using 3D hydrogel biochips, which detect tumor-associated glycans and improve sensitivity. The study analyzed sera from 33 patients with colorectal cancer, 69 healthy donors, and 27 patients with inflammatory bowel disease.
Researchers aim to reduce unnecessary surgeries and pelvic sepsis by analyzing magnetic resonance images and pathological specimens. They will develop a risk-assessment scoring system to determine which patients need surgery after chemotherapy and radiation treatments.
Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment. The U.S. Food and Drug Administration has granted PAC-1 orphan drug status for the treatment of glioblastoma multiforme, a deadly brain cancer with limited therapeutic options.
Researchers identified 2,314 genetic changes in polyps and adjacent mucosa, revealing potential drug targets for colorectal cancer prevention. The study also found similarities between premalignant and cancerous tissue, suggesting that polyps with more genetic changes may be more likely to develop into CRC.
A phase I clinical trial showed that abemaciclib achieved durable clinical activity in patients with breast cancer, non-small cell lung cancer, glioblastoma, and melanoma. Radiographic responses were observed for some patients with hormone receptor-positive breast cancer and NSCLC.
The Damon Runyon Cancer Research Foundation has selected five physician-scientists to receive the Physician-Scientist Training Award, providing them with resources to pursue cancer research. The awardees will receive grants totaling $2.3 million to aid their work in addressing the growing need for cancer research.
Researchers at Dana-Farber Cancer Institute present studies on the influence of tumor location on colorectal cancer survival, breast cancer clinical trial participation among older patients, and support for medical marijuana use in children with cancer. The findings suggest that consistent reporting of tumor location is crucial for imp...
A new study shows success with a combination therapy of the sugar 2-Deoxy-D-glucose (2-DG) and fenofibrate, which selectively starves slow-growing cancer cells while sparing normal cells. This approach eliminates toxic chemotherapy side effects, paving the way for non-toxic treatments for various cancers.
Researchers discover USP14 as a promising biomarker for predicting endometrial cancer recurrence. Women with high levels of USP14 are seven times more likely to recur than those with low levels, highlighting the potential for tailored treatment approaches.
The Samfund, a Boston-based cancer organization, will receive $8,500 from ASTRO for its work in supporting young adult cancer survivors financially. The grant funding will support the development of new financial programs and tools to aid in recovery.
A new study finds HIV-infected patients are more likely to lack cancer treatment for various cancers, including head and neck, upper gastrointestinal tract, and lung cancers. The disparity remains after adjusting for insurance status and comorbidities.
A new study published in Nature Medicine highlights the potential of big data to unlock the secrets inside cancer cells and enable more effective personalised treatments. The study proposes a blueprint for sharing patient data to improve patient outcomes.
Analysis of NCDB data shows that patients who received four quality measures had significantly higher overall median survival, increasing more than three-fold. However, compliance with these measures varies widely among patients, with only 13% receiving all four interventions.
Researchers from Memorial Sloan Kettering Cancer Center share results of experience with over 500 patients with pulmonary metastases from STS, identifying prognostic factors associated with improved survival. The study found that leiomyosarcoma histologic subtype, primary tumor size, and minimally invasive resections were significantly...
A genetic variation in the VAC14 gene is highly associated with docetaxel-induced peripheral neuropathy in prostate cancer patients. This finding could lead to more personalized treatment approaches and reduced side effects.
Research shows that 1 in 5 colorectal cancer patients are depressed at diagnosis, and this can significantly impact their quality of life. The study highlights the importance of considering psychological factors in patient care and support.
Boston Cancer Support, a nonprofit organization, will receive an $8,500 ASTRO Survivor Circle grant to support its work providing patient transportation and online resources. The organization aims to alleviate one of the largest issues faced by cancer patients: affordable transportation to treatments.
The Society of Surgical Oncology and European Society of Surgical Oncology propose a global curriculum to address training variations and inadequacies. The curriculum aims to create a robust workforce of well-trained surgical oncologists to meet the growing need resulting from the rising global cancer burden.
A new chemical sensor developed by Polish researchers can detect the presence of neopterin, a biomarker for certain cancers. The sensor uses molecular imprinting technology to capture molecules of neopterin from body fluids, with high accuracy and selectivity.
The report, based on over 3,000 patient surveys, sheds light on the physical, emotional, financial, practical, and informational needs of cancer patients during and after treatment. It aims to inform program development and address patient needs throughout their continuum of care.
Researchers discovered that cancer cells can escape the immune system by disabling the NLRC5 gene, which regulates MHC class I genes. This finding provides a new biomarker for predicting cancer patient survival and could lead to novel therapeutic strategies.
A new study found that cancer increases the risk for certain health issues beyond normal aging, including declines in activities of daily living and physical function. However, having a cancer diagnosis did not increase the likelihood of developing arthritis or vision/hearing problems, and did not exacerbate existing conditions.
A study published in Cancer Cell identified a third class of ACC, associated genes, and potential treatment targets. The research aims to provide better treatments for this rare cancer with significant side effects from current therapies.
Scientists at Helmholtz Munich discovered that fasting induces the production of a protein called GADD45β, which reduces fatty acid absorption in the liver and improves sugar metabolism. This finding holds promise for therapeutic intervention in metabolic diseases like type 2 diabetes.